10-Q · July 9, 2026
ProPhase Labs, Inc. reported a revenue of $1.2 million for Q1 2026, a decrease of 14.3% compared to $1.4 million in Q1 2025, driven by lower supplement sales. Gross margin fell to 25.3% from 36.8% year-over-year, while…
Earnings analysis · 10-Q
PRPH earnings analysis
Filed August 19, 2026 · Our reading of the company's report
The latest report
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, cash flow, and working-capital metrics cannot be…
Read full summary
The provided 10-Q excerpt does not include the income statement, balance sheet, cash-flow statement, or segment disclosures, so current-period revenue, margins, EPS, cash flow, and working-capital metrics cannot be reported. Liquidity is the principal concern: as of June 30, 2026, the Company reported approximately $5.7 million of debt against approximately $20,000 of cash and warned that it may need asset sales, debt restructuring, or additional equity capital. Sentiment is bearish due to ineffective disclosure controls, pending litigation, consumer-service issues, and newly detailed risks associated with a potential crypto treasury strategy.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
What stood out
-
Government Declines False Claims Act Intervention
The Department of Justice and relevant state authorities declined to intervene in the False Claims Act matter involving the Company’s diagnostic subsidiaries. The case remains pending, but no ongoing government investigation is known to the Company.
-
Limited Interest-Rate Exposure
Management states that a 1 percentage-point change in short-term interest rates would not materially affect future earnings, fair value, or cash flows related to cash equivalents and interest-earning marketable securities.
-
Market-Risk Exposure Unchanged
The Company reports no material changes in market-risk exposures since December 31, 2025, and states that its operations are not subject to material foreign-currency fluctuations.
What to watch
-
Severe Liquidity and Debt Mismatch
As of June 30, 2026, the Company had approximately $5.7 million of outstanding indebtedness, net of discounts, but only approximately $20,000 in cash and cash equivalents. The filing warns that insufficient operating cash flow could require asset sales, debt restructuring, or potentially highly dilutive equity capital.
-
Ineffective Disclosure Controls
Management concluded that disclosure controls and procedures were ineffective at the reasonable-assurance level as of June 30, 2026. Although no material changes to internal control over financial reporting were identified during the quarter, ineffective disclosure controls increase reporting and governance risk.
-
Potential Crypto Treasury Exposure
The filing newly details a potential crypto treasury strategy, including risks of extreme volatility, illiquidity, theft, regulatory changes, and increased stock-price volatility. The Company warns that digital assets could be irretrievably lost following a cyberattack, systems failure, or human error.
-
Consumer Complaints and Reputation Risk
DNA Complete is not BBB-rated, while Nebula Genomics has a current BBB rating of “B.” The companies reportedly fell behind in sequencing after a laboratory change, and recurring complaints about fulfillment, billing, or results access could reduce demand and increase regulatory or liability exposure.
-
Nebula Genetic-Privacy Litigation
A putative class action filed in October 2024 alleges that Nebula improperly shared customers’ genetic information without written consent under Illinois’s Genetic Information Privacy Act. The complaint remains at the pleading stage, and potential liability is not reasonably estimable.
-
Convertible-Note Default Arbitration
The Company is involved in arbitration commenced by Turnpoint Capital concerning a senior secured convertible note issued in July 2025. Turnpoint alleges events of default and seeks monetary damages, but the Company cannot estimate the potential loss, recovery, or timing.
Management's outlook
The provided 10-Q excerpt contains no quantitative revenue or EPS guidance. Management's outlook is not quantified; the filing notes that the Company may need to sell assets, restructure debt, or obtain additional equity capital if operating cash flow is insufficient.
Earlier filings 4
10-Q · July 7, 2026
ProPhase Labs, Inc.'s Q1 2026 results show a steep decline in revenue to $0.5 million from $1.4 million in the prior year, primarily due to falling supplement sales. The company remains under significant financial…
10-Q · June 30, 2026
ProPhase Labs, Inc. reported a significant decrease in net revenues of 64.3% to $0.5 million for Q1 2026 compared to $1.4 million in Q1 2025. This decline is attributed primarily to a decrease in revenue from supplement…
10-K · June 1, 2026
ProPhase Labs, Inc. reported a substantial decrease in revenue, with net revenue declining by 35.8% to $4.3 million in 2025 from $6.8 million in 2024, coupled with significant operational losses attributed to its…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.